Market Analysis, J Genet Disor Genet Rep Vol: 8 Issue: 1
Market Analysis of Glycobiology and Glycochemistry 2020
Dr. Alireza Heidari
Prof. Dr. Alireza Heidari, Ph.D., D.Sc. Full Distinguished Professor and Academic Tenure of Chemistry & Director of the BioSpectroscopy Core Research Laboratory at Faculty of Chemistry, California South University (CSU), Irvine, California, USA & President of the American International Standards Institute (AISI) Irvine, California, USA, E-mail: scholar.researcher.scientist@gmail.com
Keywords: Glycochemistry
The global glycobiology market is expected to reach USD 1,211.4 million by 2021 from USD 649.5 million in 2016, at a CAGR of 13.3%. Glycobiology is the study of carbohydrates and carbohydrate-containing biomolecules in biological processes. This study is used in diagnostics, drug discovery research, immunology, oncology, and various other applications. Glycobiology products are widely used for analysis of cell surface markers, which can act as diagnostic or therapeutic targets. The base year considered for the study is 2015, and the forecast has been provided for the period between 2016 and 2021.
Restraints
• High degree of consolidation acts as an entry barrier for new entrants
• Stringent regulatory frameworks and time-consuming approval processes
Opportunities
• Increased use of personalized medicine
• Biomarkers identification
• Developing countries and emerging markets
Challenges
• High cost of tools and instruments and their maintenance
Major players in the glycobiology market are Agilent Technologies (U.S.), Bruker Corporation (U.S.), Danaher Corporation (U.S.), New England Biolabs (U.S.), ProZyme, Inc. (U.S.), Shimadzu Corporation (Japan), Merck KGaA (Germany), Takara Bio, Inc. (Japan), Thermo Fisher Scientific (U.S.), and Waters Corporation (U.S.).
Glycobiology Market Dynamics
Drivers
• Increasing funding for Proteomics & glycomics research and growing R&D expenditure
• Growth of the proteomics market
• Technological advancements in glycomics instrumentation
Restraints
• High degree of consolidation acts as an entry barrier for new entrants
• Stringent regulatory frameworks and time-consuming approval processes
Opportunities
• Increased use of personalized medicine
• Biomarkers identification
• Developing countries and emerging markets
Challenges
• High cost of tools and instruments and their maintenance
